FDA Approves Toshiba Medical's Vantage Titan MR System -- Angioplasty.Org

Home » Imaging Center » Imaging News » Jan. 28, 2008

FDA Approves Toshiba Medical's
Vantage Titan MR System
Large Bore MR System Improves Patient Care with Reduced Noise,
Extended Field-of-View and Increased Homogeneity

related stories::
Imaging &
Diagnosis Center

All Toshiba
Press Releases

external sites:
Toshiba America
Medical Systems, Inc.

January 28, 2008 -- TUSTIN, Calif. -- Toshiba America Medical Systems, Inc., an industry leader in magnetic resonance (MR) technology, announced FDA clearance for the new open-bore 1.5T Vantage Titan™ MR system. With this clearance, Toshiba is on schedule to make the system commercially available in the first quarter of 2008. The open-bore of the Vantage Titan is 18 percent larger than other 1.5T systems on the market, featuring a large 71-centimeter patient aperture.

"Toshiba's Vantage Titan is now one of the most powerful MR units available with a 30/130 gradient platform," said Bob Giegerich, director, MR Business Unit, Toshiba. "It is a dramatic improvement over traditional open-bore 1.5T MR systems and offers the largest and widest bore available with a significant reduction in noise."

The Vantage Titan's large clinical field-of-view is unique for this bore size and produces high-quality images without compromising homogeneity or overall imaging performance. The system also features Toshiba's patented PianissimoTM noise reduction technology, which creates a better imaging experience for all patients.

The Vantage Titan MR system also takes advantage of Toshiba's proprietary, contrast-free MRA techniques - Fresh Blood Imaging (FBI), Contrast-free Improved Angiography (CIA), Time-Spatial Labeling Inversion Pulse (Time-SLIP) and Time-Slip Angiography (TSA). Contrast-free imaging is particularly important because gadolinium, the most common contrast agent used for magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) exams, has been directly linked to a sometimes fatal disease that occurs in patients with renal insufficiency, called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).

About Toshiba
With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. Toshiba Medical Systems Corp., an independent group company of Toshiba Corp., is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, Cath & EP Labs, X-ray, Ultrasound, Nuclear Medicine, MRI and information systems. Toshiba Corp. is a leader in information and communications systems, electronic components, consumer products, and power systems. Toshiba has approximately 191,000 employees worldwide and annual sales of $60 billion. For more information, visit www.medical.toshiba.com.

Source: Toshiba America Medical Systems

(Disclaimer: external links to news, press releases and other timely information sources are provided as a service by Angioplasty.Org, which is not responsible for the content found on any external sites. Items marked with a ($$) indicate that the external site normally restricts viewing to paid subscribers. Other sites may require free registration.

Angioplasty.Org Home • PatientCenter

send comments & suggestions to "info at angioplasty dot org"
read Terms of Use and Privacy statement

Angioplasty.Org is an independent educational health site
The Imaging and Diagnosis Section of Angioplasty.Org is sponsored by
Toshiba America Medical Systems
Unless otherwise noted, all content, including text, photos and video
© Copyright Venture Digital LLC 1996-2009